Biological
Goflikicept clinical trials
Also written RPH-104.
- studies test it
- 14
- open now
- 3
- in phase 3
- 7
- first study started
- 2016
Keep track of what changes. Save the goflikicept studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Development codes
Studies by the year they started
14 studies that test it; most in 2020 (4)
| Year | Studies |
|---|---|
| 2016 | 1 |
| 2018 | 1 |
| 2020 | 4 |
| 2021 | 2 |
| 2023 | 2 |
| 2024 | 1 |
| 2025 | 1 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 2
- Phase 2
- 8
- Phase 3
- 7
What it is tested for
Each study’s main condition, where its own words name it.
- Gout
- 1
Who runs them
Industry 14 · Other 0
R-Pharm International, LLC (8) · R-Pharm Overseas, Inc. (3) · R-Pharm (3)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses goflikicept is read from its arms, and is right about nine times in ten.
Testing it · 14
- Goflikicept for Resolution and Prevention of Attacks in Pediatric and Adolescent Patients With Colchicine-Resistant or Colchicine-Intolerant Familial Mediterranean FeverNot yet recruitingPhase 3R-PharmNCT07880886Written as RPH-104
- Study of the Efficacy and Safety of Goflikicept and Olokizumab as the Second-line Therapy in Patients With Still's DiseaseNot yet recruitingPhase 3R-Pharm International, LLCNCT07625384Written as Goflikicept
- Safety and Efficacy of RPH-104 Used to Prevent Recurrent Fever Attacks in Adult Patients With Colchicine Resistant or Colchicine Intolerant Familial Mediterranean FeverRecruitingPhase 2R-Pharm International, LLCNCT05190991Written as RPH-104
- Pharmacokinetics, Safety and Immunogenicity of RPH-104 at a New Dosage and Different Doses Via Single Subcutaneous and Intravenous Administration in Healthy VolunteersCompletedPhase 1R-Pharm International, LLCNCT07206043Written as RPH-104 80 mg
- Efficacy and Safety of RPH-104 for Resolution and Prevention of Recurring Attacks in Adult Subjects With Familial Mediterranean Fever With Resistance to or Intolerance of ColchicineActive, not recruitingPhase 2R-Pharm International, LLCNCT05092776Written as RPH-104
- Study of the Safety and Efficacy of RPH-104 in Preventing Recurrences in Patients With Idiopathic Recurrent PericarditisActive, not recruitingPhase 3R-Pharm International, LLCNCT05673902Written as RPH-104
- Efficacy and Safety of RPH-104 Treatment in Patients With Recurrent PericarditisSuspendedPhase 2/3R-Pharm Overseas, Inc.NCT05107934Written as RPH-104
- Efficacy and Safety Clinical Study of RPH-104 in Adult Onset Still's Disease (AOSD)WithdrawnPhase 3R-Pharm International, LLCNCT05432960Written as RPH-104
- Study of the Efficacy and Safety of RPH-104 in Adult Subjects With Schnitzler SyndromeWithdrawnPhase 2R-Pharm Overseas, Inc.NCT04213274Written as 80 mg RPH-104
- Study to Evaluate the Effect on Parameters of Systemic Inflammation and Disease Outcomes and Safety of RPH-104 in Subjects With Acute ST-elevation Myocardial InfarctionCompletedPhase 2R-Pharm Overseas, Inc.NCT04463251Written as RPH-104 80 mg
- Study to Evaluate the Efficacy and Safety of RPH-104 Treatment in Patients With Idiopathic Recurrent PericarditisCompletedPhase 2/3R-Pharm International, LLCNCT04692766Written as RPH-104
- Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Evaluation of RPH-104 Administered at Different Doses to Patients With Acute Gout AttackTerminatedPhase 2R-PharmNCT04067492Written as RPH - 104
- Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19)CompletedPhase 2/3R-Pharm International, LLCNCT04380519Written as RPH-104 80 mg
- Pharmacokinetics and Pharmacodynamics of RPH-104 in Healthy SubjectsCompletedPhase 1R-PharmNCT02667639Written as RPH-104
Codes
What other systems call goflikicept · ClinicalTrials.gg INT014257
- UNII (FDA) 11DRN01OK2GOFLIKICEPTOne source FDA
- NCI Thesaurus C177057GoflikiceptOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 11DRN01OK2 | GOFLIKICEPT | One source FDA |
| NCI Thesaurus | C177057 | Goflikicept | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.